ALT241206P2000
- 0.00
- 0.000.00%
Altimmune Newsroom
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
Express News | US weight loss drug concept stocks rose across the board, with Viking Therapeutics up more than 5%, Altimmune and Eli Lilly and Co up more than 3%, Sorrento Biologicals and Novo-Nordisk A/S up more than 2%. Previously, US President Biden proposed medical
Amgen (AMGN.US) releases mid-term data for weight loss therapy MariTide, with weight loss results comparable to Novartis.
Amgen announced on Tuesday that its experimental weight loss therapy MariTide has achieved significant results in Phase 2 trials.
Altimmune to Participate at Two Upcoming Investor Conferences
White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs
Executive Reshuffles: TWO, CYBR, PFG and ALT
Altimmune Presents New Data On The Effect Of Pemvidutide On Inflammatory Lipids In Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease At The Liver Meeting 2024
Altimmune Third Quarter 2024 Earnings: Beats Expectations
Eli Lilly and Co. is startled, novo-nordisk a/s saves the day! The market prospects for weight loss drugs still tempt many players.
The weight loss drug market still has a broad prospect, with most institutions predicting that the market size will reach the trillion-dollar level by the end of this decade.
10 Health Care Stocks With Whale Alerts In Today's Session
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $12
Altimmune's Pemvidutide Progress and Expansion: A Buy Recommendation by Patrick Trucchio
Evercore Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25
B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20
Altimmune | 10-Q: Q3 2024 Earnings Report
Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday
Altimmune Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, UBS Initiated Coverage on the Stock With a Buy Rating and Announced a Price Target of $26.
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Altimmune | 8-K: Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
Altimmune Appoints Gregory Weaver as CFO for Growth